CD274 and neoplasm: Several factors, including mismatch repair deficiency (dMMR)/microsatellite instability (MSI), TMB, tumor PD-L1 expression, and host-specific immunity characteristics, such as the microbiome or germline genetics of the host, can affect the response to immune checkpoint inhibitor-based therapy by determining the immunogenicity of tumors (Le et al., 2015; Ott et al., 2019; Baruch et al., 2021; Doroshow et al., 2021; Sayaman et al., 2021).